

# Awakn Life Sciences' Anthony Tennyson on using researched backed psychedelic drugs and therapies to treat Alcohol Use Disorder

written by InvestorNews | June 29, 2021

In a recent InvestorIntel interview, Tracy Weslosky speaks with Anthony Tennyson, CEO of [Awakn Life Sciences Corp.](#) (NEO: AWKN) about Awakn's commitment to use researched backed psychedelic drugs and therapies to treat addictions such as Alcohol Use Disorder.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Anthony went on to say that Alcohol Use Disorder affects 5% of the global population with a 70% relapse rate within the 1st 12 months and accounts for 30% of the global addiction treatment market. Anthony further said that as clinics start to rollout this year starting with the UK, "Awakn will be the only company in the world providing evidence backed ketamine-assisted psychotherapy for Alcohol Use Disorder."

To watch the full interview, [click here](#)

## About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn's team consists of world leading chemists, scientists, psychiatrists, and

psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.

To learn more about Awakn Life Sciences Corp., [click here](#)

**Disclaimer:** Awakn Life Sciences Corp. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or

results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email [info@investorintel.com](mailto:info@investorintel.com).

---

## **Anthony Tennyson on Awakn Life Sciences bringing innovation in addiction treatment to the market**

written by InvestorNews | June 29, 2021

In a recent InvestorIntel interview, Tracy Weslosky speaks with Anthony Tennyson, CEO of [Awakn Life Sciences Corp.](#) (NEO: AWKN) about Awakn's recent [listing](#) on the NEO Exchange and bringing evidence-backed psychedelic therapies for addiction to the market.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Anthony went on to say that Awakn is a biotech company that develops and delivers addiction treatment using psychedelic inspired drugs and therapies backed by research evidence and a team of world leading scientists, psychiatrists, and psychologists. With 15-20% of the UK, EU, US and Canadian

population suffering from Addiction, Anthony said “the current industry is not as effective as it should be and there hasn’t been an innovation in addiction treatment in many years. We are going to change that.”

To watch the full interview, [click here](#)

### **About Awakn Life Sciences Corp.**

Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.

To learn more about Awakn Life Sciences Corp., [click here](#)

**Disclaimer:** Awakn Life Sciences Corp. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the

date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [www.Sedar.com](http://www.Sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email [info@investorintel.com](mailto:info@investorintel.com).

---

**Newly listed Awakn Life Sciences' team of experts prepare a pathway to treat**

# addiction through psychedelic medicines

written by InvestorNews | June 29, 2021

One of the largest problems in our society today is substance abuse and addiction. Almost [21 million](#) Americans have at least one addiction. Addiction (drugs, tobacco, and alcohol etc) kills thousands of Americans every year and impacts millions of lives. For example, mental health and addictions are the 5th leading cause of illness globally, affecting [20% of the global population](#).

Today's company is in the sector of biotechnology and focuses on research and treatment to treat addiction and other mental disorders. They have already assembled a very impressive team.

**15-20% of the population in USA, EU, UK & Canada are affected by addiction**



Source: [Awakn Life Sciences company presentation](#)

[Awakn Life Sciences Corp.](#) (NEO: AWKN) ("Awakn") [listed yesterday](#) on the [NEO Exchange Inc.](#) in Canada under the symbol "AWKN", after a reverse merger and raise of gross proceeds of approximately [US\\$8.3 million](#) through a brokered private placement. Awakn is a biotechnology company with clinical operations that researches, develops, and delivers psychedelic and other medicines to treat addiction. The Company also plans to use psychedelic medicines to treat other mental health conditions.

Awakn CEO, Anthony Tennyson, [stated](#):

“Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics....**The NEO listing will enable us to accelerate the execution of our drug discovery, therapy development, advanced analytics, and open clinic roll out programs.**”

Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies and enabling technologies to treat addiction. Awakn [state](#):

“Psychedelics and Psychedelic-Assisted Psychotherapy...have the potential to radically change Addiction treatment and deliver significantly better patient outcomes.”

### **Awakn’s business strategy**

Awakn has a dual strategic focus of researching and developing psychedelic drugs/therapies/enabling technologies and delivering psychedelic treatments.

Awakn’s research will focus on developing next generation psychedelic drugs to treat addiction, including MDMA for alcohol use disorder, and ketamine for addiction. Awakn also intends to research for new chemical entities that can be effective treatment for alcohol, behavioural, opioid, and tobacco addictions.

Awakn plans to deliver evidence-backed psychedelic therapies for addiction in clinics in the UK and Europe and through licensing partnerships globally. The Company also plans to use psychedelic medicines to treat other mental health conditions.

### **Awakn’s team (Board, management, advisors)**

The Awakn team is simply very impressive. You can read the full details [here](#). Needless to say the Awakn team consists of several Doctors, Professors, and experienced personnel in the addictive disorders specialty. In news released today, Awakn [announced](#) that they have appointed globally renowned Neuroscientist and addiction researcher, Professor David Nutt, to the role of Chief Research Officer. Awakn state:

“This appointment is driven by the expansion of Awakn’s psychedelic drug and therapy development pipeline targeting Addiction. In particular, the identification, and development of several potential new candidates with unique properties to better treat a broad range of addictions, acquired from Prof. David Nutt’s Equasy Enterprises in March 2021; the licencing of the intellectual property from world’s only Ketamine-Assisted Psychotherapy trial for Alcohol Use Disorder (AUD) from the University of Exeter in March 2021. And finally, the world’s only Phase IIb trial for MDMA-Assisted Psychotherapy for AUD.”

**Awakn has a highly experienced board and team**



Source: [Awakn Life Sciences company presentation](#)

### **Closing remarks**

Addiction of all types (alcohol, tobacco, drugs) is a significant societal problem with a strong need for urgent solutions. The global substance addiction treatment industry is valued at US\$17.5 billion pa and is forecast [to increase to US\\$31.5 billion pa by 2027](#).

Awakn Life Sciences has assembled a world class team to research and treat both addiction and other mental disorders. For those investors lucky enough to be able to access the NEO Exchange in



Canada then be sure to take a look at Awakn Life Sciences. InvestorIntel will also keep you up to date [here](#) with their latest news and progress in 2021.